Company / Current Assets
Barinthus Biotherapeutics plc. Current Assets History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$77.8M
FY2025
5-year range
$77.8M / $226.8M
FY2021-FY2025
Trend
-38.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Assets has declined for 4 consecutive years, from $227M in FY2021 to $78M in FY2025.
Based on SEC 10-K filings.
$78M in FY2025 with a 3-year CAGR of -28.5%.
Declined from $157M to $78M over the past 2 years.
Current Assets over time
Growth rates
- 3-Year CAGR
- -28.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Barinthus Biotherapeutics plc.'s current assets has declined for 4 consecutive years.
- 3-year CAGR of -28.5%, indicating a declining trend.
- In FY2025, current assets decreased 38.1% year-over-year.
- Peak current assets was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.06 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $77.8M | -38.1% |
| FY2024 | $125.7M | -19.9% |
| FY2023 | $156.9M | -26.3% |
| FY2022 | $213.0M | -6.1% |
| FY2021 | $226.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026